New drug vixarelimab tested for Tough-to-Treat ulcerative colitis
NCT ID NCT06693908
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage trial is testing a drug called vixarelimab in 24 people with moderate to severe ulcerative colitis who have not improved with standard treatments. The study looks at how the drug affects the gut, how it moves through the body, and whether it is safe. It is too early to know if it will help symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vixarelimab
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe ulcerative colitis who have not responded to other therapies.
What could go wrong
This is a very early, small study (24 people) focused on safety and biological effects, not yet on symptom improvement. The drug may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Research Organisation GmbH
Berlin, 10117, Germany